Results 91 to 100 of about 3,710 (152)

Riociguat: an upcoming therapy in chronic thromboembolic pulmonary hypertension?

, 2010
Although pulmonary endarterectomy remains the treatment of choice for patients with chronic thromboembolic pulmonary hypertension (CTEPH), not all patients will benefit from or receive this highly specialised surgery.
N. H. Kim
core  

Effective arterial elastance relates more closely to pulsatile than resistive indices during routine haemodynamic assessment of inoperable chronic thromboembolic pulmonary hypertension. [PDF]

ERJ Open Res
Chemla D, Jaïs X, Jevnikar M, Brenot P, Gerges C, Beurnier A, Boucly A, Savale L, Sitbon O, Humbert M, Hervé P, Montani D.   +11 more
europepmc   +1 more source

Riociguat as inpatient rescue therapy for acute decompensation of inoperable chronic thromboembolic pulmonary hypertension. [PDF]

BMJ Case Rep
Alsufyani RH, Imran S, Mccullagh B, Hassan T.   +3 more
europepmc   +1 more source

Riociguat versus sildenafil on hypoxic pulmonary vasoconstriction and ventilation/perfusion matching

Introduction Current treatment with vasodilators for pulmonary hypertension associated with respiratory diseases is limited by their inhibitory effect on hypoxic pulmonary vasoconstriction (HPV) and uncoupling effects on ventilation-perfusion (V'/Q ...
Moreno, Laura, Esquivel-Ruiz, Sergio, Morales-Cano, Daniel, Milara, Javier, Cortijo, Julio, Barreira, Bianca, Cogolludo, Ángel, Chamorro, Virginia, Callejo, María, Barberà i Mir, Joan Albert, Mondejar-Parreño, Gema, Perez-Vizcaino, Francisco   +11 more
core  

STOP-RIO study: protocol for a randomised, controlled, open-label non-inferiority trial to test the safety of discontinuation of riociguat after balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension. [PDF]

BMJ Open
Rodenburg TC, Boerman S, Post M, Bogaard HJ, Aman J.   +4 more
europepmc   +1 more source

Synergistic modulation of cAMP and cGMP rescues hemin-induced plasma membrane fragmentation. [PDF]

J Biol Chem
Laspa Z, Rohlfing AK, Fischer M, Kollotzek F, Castor T, Borst O, Sowa PW, Sigle M, Harm T, Gawaz MP.   +9 more
europepmc   +1 more source

Multimodal Management of Chronic Thromboembolic Pulmonary Hypertension: A Narrative Review of Treatment Selection and Sequencing. [PDF]

J Cardiovasc Dev Dis
Gharsalli H, Alshahrani M, Harbi O, Alwadai N, Al-Asiri AM, Alahmari F, Alqahtani A, Al-Jahash N, Abbag L, Alqahtani S, Amer KA.   +10 more
europepmc   +1 more source

Biomarker analysis from the phase 2b randomized placebo-controlled trial of riociguat in early diffuse cutaneous systemic sclerosis [PDF]

OBJECTIVE: To examine disease and target engagement biomarkers in the RISE-SSc trial of riociguat in early diffuse cutaneous systemic sclerosis and their potential to predict the response to treatment.
Smith, Vanessa, Wosnitza, Melanie, Truchetet, Marie-Elise, Khanna, Dinesh, Riccieri, Valeria, Schiopu, Elena, Denton, Christopher P, Johnson, Sindhu R, Silver, Richard M, Ishikawa, Osamu, Ghadessi, Mercedeh, Atsumi, Tatsuya, Stagnaro, Chiara, Czirják, László, Stevens, Wendy, Bečvář, Radim, Hachulla, Eric, Allanore, Yannick, Distler, Oliver, Ishii, Tomonori, Kuwana, Masataka, Kramer, Frank, Sandner, Peter, De Langhe, Ellen, Szücs, Gabriella, Steen, Virginia, Matucci-Cerinic, Marco, Höfler, Josef, Pope, Janet E   +28 more
core  

Role of ROS, soluble guanylate cyclase and cGMP in mouse lung development during hyperoxia. [PDF]

Am J Physiol Heart Circ Physiol
Nguyen ML, Taylor JM, Dudley VJ, Waypa GB, Schumacker PT.   +4 more
europepmc   +1 more source

Mechanisms Underlying the Biphasic Effects of Hydrogen Sulfide in Rat Intrapulmonary Arteries. [PDF]

Biomedicines
Tunaitytė A, Alan E, Aleknavičius A, Abramavičius S, Simonsen U, Stankevičius E.   +5 more
europepmc   +1 more source